Sugi Predict

Sugi Predict / Compounds / SCHEMBL2799300

SCHEMBL2799300

SCHEMBL2799300

CC(C)(C)OC(=O)NCC(Cc1ccc(Cl)cc1)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 2/20 0.50
▸ PPARG P37231 3/20 0.49
▸ EPHX2 P34913 1/20 0.49
▸ PPARA Q07869 3/20 0.48
▸ KMT2A Q03164 2/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ SYK P43405 1/20 0.44
▸ ATM Q13315 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CTSS P25774 6/20 0.43
▸ CTSK P43235 5/20 0.43
▸ DRD2 P14416 1/20 0.42
▸ CTSL P07711 1/20 0.42
▸ CTSB P07858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2799041 1.00 GAA (0.50) GAAPPARGEPHX2PPARAKMT2A
SCHEMBL3665503 0.88 GAA (0.49) GAAPPARGEPHX2PPARAKMT2A
SCHEMBL825959 0.88 ATM (0.55) GAAKMT2AMEN1SYKATM
SCHEMBL1186455 0.88 ATM (0.55) GAAKMT2AMEN1SYKATM
SCHEMBL3825012 0.88 ATM (0.55) GAAKMT2AMEN1SYKATM
SCHEMBL3668701 0.87 GAA (0.55) GAAPPARGEPHX2PPARAKMT2A
SCHEMBL3697318 0.87 CTSS (0.56) GAAKMT2AMEN1SYKATM
SCHEMBL12101475 0.87 MEN1 (0.47) GAAKMT2AMEN1SYKATM
SCHEMBL16798329 0.87 CTSS (0.56) GAAPPARGEPHX2KMT2AMEN1
SCHEMBL2795545 0.86 KMT2A (0.64) GAAPPARGEPHX2PPARAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11376260-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2022-07-05 — — US disclosed
US-20210106593-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2021-04-15 — — US disclosed
US-10842799-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2020-11-24 — — US disclosed
US-20200078371-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2020-03-12 — — US disclosed
US-20190192534-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2019-06-27 — — US disclosed
US-10278975-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2019-05-07 — — US disclosed
WO-2018184976-A1 SUBSTITUTED IMIDAZO[1,2-A]PYRIDINECARBOXAMIDES AND USE OF SAME BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2018-10-11 — — WO disclosed
EP-3077401-B1 SERINE/THREONINE KINASE INHIBITORS GENENTECH INC (US) 2018-04-18 — — EP disclosed
US-9867833-B2 Serine/threonine kinase inhibitors GENENTECH, INC. (US) 2018-01-16 — — US disclosed
US-20180000833-A1 SERINE/THREONINE KINASE INHIBITORS GENENTECH, INC. (US) 2018-01-04 — — US disclosed
EP-2242755-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-10-27 — — EP disclosed
EP-2242757-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2010-10-27 — — EP disclosed
US-20100168123-A1 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. 2010-07-01 — — US disclosed
WO-2009089352-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 — — WO disclosed
WO-2009089359-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 — — WO disclosed
WO-2009089359-A1 PYRAZOLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 — — WO disclosed
WO-2009089352-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-07-16 — — WO disclosed
EP-1684694-A2 AKT PROTEIN KINASE INHIBITORS Array Biopharma, Inc. (US) 2006-08-02 — — EP disclosed
US-20050130954-A1 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline ARRAY BIOPHARMA INC. 2005-06-16 — — US disclosed
WO-2005051304-A2 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2005-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376260-B2 Serine/threonine kinase inhibitors MAP3K1, MAP3K4, MAP4K2 GAA 3060/4885PPARG 4471/4885EPHX2 3208/4885
US-10842799-B2 Serine/threonine kinase inhibitors MAP3K1, MAP3K4, MAP4K2 GAA 3060/4885PPARG 4471/4885EPHX2 3208/4885
US-20100168123-A1 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 GAA 2160/4885PPARG 3267/4885EPHX2 3797/4885
US-20180000833-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 GAA 3060/4885PPARG 4471/4885EPHX2 3208/4885
US-10278975-B2 Serine/threonine kinase inhibitors MAP3K1, MAP3K4, MAP4K2 GAA 3060/4885PPARG 4471/4885EPHX2 3208/4885
US-20190192534-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 GAA 3060/4885PPARG 4471/4885EPHX2 3208/4885
US-20210106593-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 GAA 3060/4885PPARG 4471/4885EPHX2 3208/4885
US-20200078371-A1 SERINE/THREONINE KINASE INHIBITORS MAP3K1, MAP3K4, MAP4K2 GAA 3060/4885PPARG 4471/4885EPHX2 3208/4885
US-20050130954-A1 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline MTOR, CDK2, CLK2 GAA 3630/4885PPARG 2285/4885EPHX2 4004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.